JP2004524023A - 選択的癌療法のための特異的ヒト抗体 - Google Patents

選択的癌療法のための特異的ヒト抗体 Download PDF

Info

Publication number
JP2004524023A
JP2004524023A JP2002559551A JP2002559551A JP2004524023A JP 2004524023 A JP2004524023 A JP 2004524023A JP 2002559551 A JP2002559551 A JP 2002559551A JP 2002559551 A JP2002559551 A JP 2002559551A JP 2004524023 A JP2004524023 A JP 2004524023A
Authority
JP
Japan
Prior art keywords
peptide
polypeptide
seq
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002559551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524023A5 (enExample
Inventor
ハガイ，ヨチェブド
ラザロビッツ，ジャネット
ギュイ，ラケル
リップスチツ，オルリー
スザントン，エスザー
レバノン，アビグダー
プラクシン，ダニエル
ペレツ，トゥビア
Original Assignee
バイオ テクノロジー ジェネラル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ テクノロジー ジェネラル コーポレイション filed Critical バイオ テクノロジー ジェネラル コーポレイション
Publication of JP2004524023A publication Critical patent/JP2004524023A/ja
Publication of JP2004524023A5 publication Critical patent/JP2004524023A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2002559551A 2000-12-29 2001-12-31 選択的癌療法のための特異的ヒト抗体 Pending JP2004524023A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (2)

Publication Number Publication Date
JP2004524023A true JP2004524023A (ja) 2004-08-12
JP2004524023A5 JP2004524023A5 (enExample) 2005-05-26

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002559551A Pending JP2004524023A (ja) 2000-12-29 2001-12-31 選択的癌療法のための特異的ヒト抗体

Country Status (15)

Country Link
EP (1) EP1353937A4 (enExample)
JP (1) JP2004524023A (enExample)
KR (1) KR20030091952A (enExample)
CN (1) CN100374456C (enExample)
AU (1) AU2002246737B2 (enExample)
BR (1) BR0116763A (enExample)
CA (1) CA2433227A1 (enExample)
CZ (1) CZ20031983A3 (enExample)
HU (1) HUP0400775A2 (enExample)
IL (1) IL156690A0 (enExample)
MX (1) MXPA03005944A (enExample)
NZ (1) NZ527173A (enExample)
PL (1) PL365758A1 (enExample)
RU (1) RU2316564C2 (enExample)
WO (1) WO2002059264A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520089A (ja) * 2015-04-22 2018-07-26 ユーシービー バイオファルマ エスピーアールエル タンパク質精製の方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
KR20060107501A (ko) * 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
BR112013000452A2 (pt) * 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
PL3590962T3 (pl) * 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CR20220578A (es) * 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520089A (ja) * 2015-04-22 2018-07-26 ユーシービー バイオファルマ エスピーアールエル タンパク質精製の方法

Also Published As

Publication number Publication date
CN1551886A (zh) 2004-12-01
WO2002059264A2 (en) 2002-08-01
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
EP1353937A2 (en) 2003-10-22
CZ20031983A3 (cs) 2005-07-13
WO2002059264A3 (en) 2003-03-06
KR20030091952A (ko) 2003-12-03
PL365758A1 (en) 2005-01-10
IL156690A0 (en) 2004-01-04
NZ527173A (en) 2006-03-31
BR0116763A (pt) 2004-03-09
CA2433227A1 (en) 2002-08-01
EP1353937A4 (en) 2005-04-13
RU2003123100A (ru) 2005-03-10
MXPA03005944A (es) 2005-04-29
HUP0400775A2 (en) 2007-05-02
RU2316564C2 (ru) 2008-02-10

Similar Documents

Publication Publication Date Title
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
AU2001249760B2 (en) Mucin-1 specific binding members and methods of use thereof
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) Specific human antibodies for selective cancer therapy
US20090220486A1 (en) Antibodies and uses thereof
KR102698752B1 (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
JP2005503756A (ja) 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
JP2005503756A5 (enExample)
JP2007528711A (ja) 抗体及びその使用
CA2491363A1 (en) Antibodies and uses thereof
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
US20110117602A1 (en) Human antibody capable of inducing apoptosis
US20040208877A1 (en) Antibodies and uses thereof
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080401